NCT06162572
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 26 versions: 25 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites reduced: 56 → 52 locations
- Eligibility criteria expanded, about 22 words
- Secondary endpoints: details revised at 2 of 16 entries
- Minor Trial sites reduced: 63 → 56 locationsv25
- Minor Enrollment target: 101 to 102v24
- Minor Enrollment target: 100 to 101v23
- Minor Enrollment target: 74 to 100v22
Show 19 earlier versionsHide 19 earlier versions
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 176 to confirmed 74
- Study sites: 73 to 63
- Minor Study sites revised (73)v20
- Minor Site details revised at 1 of 73 sitesv19
- Minor Eligibility criteria revised
- Site details revised at 11 of 73 sites
- Minor Site details revised at 1 of 73 sitesv17
- Minor Site details revised at 3 of 73 sitesv16
- Minor Site details revised at 3 of 73 sitesv15
- Minor Site details revised at 6 of 73 sitesv14
- Minor Site details revised at 3 of 73 sites
- Eligibility criteria expanded, about 4 words
- Minor Site details revised at 2 of 73 sitesv12
- Minor Site details revised at 4 of 73 sitesv11
- Minor Study sites revised (73)v10
- Minor Study sites revised (73)v9
- Minor Study sites: 72 to 73
- Start date changed from estimate of Aug 31, 2024 to Aug 7, 2024
- Notable Start date: Jul 26, 2024 to Aug 31, 2024
- Study sites: 8 to 72
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Jun 7, 2024 to Jul 26, 2024
- Site details revised at 8 of 8 sites
- Minor Study sites: 0 to 8v4
- Notable Start date: Apr 30, 2024 to Jun 7, 2024v3
- Minor Start date: Apr 1, 2024 to Apr 30, 2024v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (16)
Show 11 moreShow less
Arms and interventions
Part A: Combination-therapy safety lead-in
Part A: Combination-therapy safety lead-in
Part A: Combination-therapy safety lead-in
Part B: Randomized dose expansion
Part B: Randomized dose expansion
Part B: Randomized dose expansion
Part B: Randomized dose expansion
Drugs: S095018, S095024, S095029, S095018 Recommended Dose Expansion (RDE), S095024 RDE, S095029 RDE, Cemiplimab
Sites
52 sites in 13 countries
Brazil 11, Italy 9, Spain 6, France 5, Australia 4, Hungary 3, United Kingdom 3, United States 3, Austria 2, Belgium 2, Taiwan 2, Hong Kong 1, Romania 1